Summary

A post hoc analysis of data from > 2000 patients from the CAP-START trial found that macrolide antibiotic use in hospitalized patients with community-acquired pneumonia resulted in an increased risk of cardiac events, including arrhythmia and heart failure, compared with patients who received other antibiotic therapies.